Brooklyn ImmunoTherapeutics (NYSE:BTX) Research Coverage Started at StockNews.com

StockNews.com began coverage on shares of Brooklyn ImmunoTherapeutics (NYSE:BTX) in a research report sent to investors on Friday. The firm issued a hold rating on the stock.

Brooklyn ImmunoTherapeutics Price Performance

BTX opened at $2.24 on Friday. Brooklyn ImmunoTherapeutics has a 12 month low of $0.17 and a 12 month high of $10.10. The stock has a market capitalization of $131.77 million, a P/E ratio of -0.99 and a beta of 4.61. The business has a 50 day simple moving average of $2.14 and a 200-day simple moving average of $1.81.

Institutional Trading of Brooklyn ImmunoTherapeutics

A hedge fund recently raised its stake in Brooklyn ImmunoTherapeutics stock. Renaissance Technologies LLC raised its stake in Brooklyn ImmunoTherapeutics Inc (NYSE:BTX) by 20.1% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 1,459,626 shares of the company’s stock after buying an additional 243,826 shares during the period. Renaissance Technologies LLC owned approximately 2.48% of Brooklyn ImmunoTherapeutics worth $360,000 at the end of the most recent reporting period. Institutional investors own 26.00% of the company’s stock.

About Brooklyn ImmunoTherapeutics

Eterna Therapeutics, Inc is a clinical stage biopharmaceutical company, which engages in creating transformative regenerative medicine treatments for cancer, blood disorders, and monogenic diseases. It offers IRX-2, a human cell-derived cytokine therapy, studying the safety and efficacy of IRX-2 in patients with head and neck cancer in Phase 2B.